Abstract
AGO-OVAR-12, a double-blind phase III trial randomised 1366 patients (2:1) with FIGO stage IIB-IV ovarian cancer (OC) to either to receive six cycles of carboplatin and paclitaxel with nintedanib or placebo after upfront debulking surgery.
AGO-OVAR-12, a double-blind phase III trial randomised 1366 patients (2:1) with FIGO stage IIB-IV ovarian cancer (OC) to either to receive six cycles of carboplatin and paclitaxel with nintedanib or placebo after upfront debulking surgery.